false000163605000016360502022-01-192022-01-19

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 19, 2022
Sio Gene Therapies Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-37418
85-3863315
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
130 West 42nd Street
26th Floor
New York, New York 10036
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code): +1 877 746 4891
N/A
(Former name, former address and former fiscal year, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities Registered pursuant to Section 12(b) of the Act:
Title of each Class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.00001 per share
SIOX
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 19, 2022, the Compensation Committee of the Board of Directors of Sio Gene Therapies Inc. (the "Registrant") adopted a retention program for all of the Registrant's employees, including its executive officers (the "Retention Program").

Under the Retention Program, each employee employed on a full-time basis as of January 19, 2022 will be eligible to receive a cash retention bonus totaling 100% of such participant's current target annual bonus for the fiscal year ending March 31, 2023, in addition to such participant's regular target annual bonus for such fiscal year. The retention bonus will be paid in three equal installments on July 15, 2022, October 14, 2022 and January 13, 2023, subject to each participant’s continued full-time employment through the applicable payment date. The Retention Program does not modify the existing terms of existing employment arrangements as well as the Registrant’s annual cash bonus plan.

The foregoing summary of the material terms of the Retention Program does not purport to be complete and is subject to, and qualified in its entirety by reference to, a description of the terms of the Retention Program approved by the Compensation Committee of the Registrant’s Board of Directors. The Registrant intends to file such a copy of the Retention Plan with its Annual Report on Form 10-K for the fiscal year ending March 31, 2022.




SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SIO GENE THERAPIES INC.
Dated:
January 25, 2022
By:
/s/ David Nassif
Name:
David Nassif
Title:
Chief Financial Officer and General Counsel


Axovant Gene Therapies (NASDAQ:AXGT)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Axovant Gene Therapies Charts.
Axovant Gene Therapies (NASDAQ:AXGT)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Axovant Gene Therapies Charts.